Not logged in Developmental mosaicism underlying EGFR-mutant lung cancer presenting with multiple primary tumors Burr, Risa; Leshchiner, Ignaty; Costantino, Christina L.; Blohmer, Martin; Sundaresan, Tilak; Cha, Justin; Seeger, Karsen; Guay, Sara; Danysh, Brian P.; Gore, Ira; Jacobs, Raquel A.; Slowik, Kara; Utro, Filippo; Rhrissorrakrai, Kahn; Levovitz, Chaya; Barth, Jaimie L.; Dubash, Taronish; Chirn, Brian; Parida, Laxmi; Sequist, Lecia V.; Lennerz, Jochen K.; Mino-Kenudson, Mari; Maheswaran, Shyamala; Naxerova, Kamila; Getz, Gad; Haber, Daniel A. Share Save
Overall survival with neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): A randomised, double-blind, placebo-controlled, phase 3 trial Holmes, Frankie A.; Moy, Beverly; Delaloge, Suzette; Chia, Stephen K. L.; Ejlertsen, Bent; Mansi, Janine; Iwata, Hiroji; Gnant, Michael; Buyse, Marc; Barrios, Carlos H.; Silovski, Tajana; Separovic, Robert; Bashford, Anna; Zotano, Angel Guerrero; Denduluri, Neelima; Patt, Debra; Gokmen, Erhan; Gore, Ira; Ii, John W. Smith; Loibl, Sibylle; Masuda, Norikazu; Tomasevic, Zorica; Petrakova, Katarina; DiPrimeo, Daniel; Wong, Alvin; Martin, Miguel; Chan, Arlene Share Save
Mechanisms of genetic predisposition to multifocal lung cancer Burr, Risa; Leshchiner, Ignaty; Costantino, Christina L.; Blohmer, Martin; Sundaresan, Tilak; Cha, Justin; Seeger, Karsen; Guay, Sara; Danysh, Brian P.; Gore, Ira; Jacobs, Raquel A.; Slowik, Kara; Utro, Filippo; Rhrissorrakrai, Kahn; Levovitz, Chaya; Barth, Jaimie L.; Dubash, Taronish; Chirn, Brian; Parida, Laxmi; Sequist, Lecia V.; Mino-Kenudson, Mari; Naxerova, Kamila; Maheswaran, Shyamala; Getz, Gad; Haber, Daniel A. Share Save
Long-Term Safety and Survival With Gefitinib in Select Patients With Advanced Non-Small Cell Lung Cancer: Results From the US IRESSA Clinical Access Program (ICAP) Hirsch, Fred R.; Sequist, Lecia V.; Gore, Ira; Mooradian, Meghan; Simon, George; Croft, Elisabeth F.; DeVincenzo, Diana; Munley, Jiefen; Stein, Dara; Freivogel, Klaus; Sifakis, Frangiscos; Bunn, Paul A., Jr. Share Save
Effects of adding budesonide or colestipol to loperamide prophylaxis on neratinib-associated diarrhea in patients (pts) with HER2+early-stage breast cancer (eBC): the CONTROL trial Ibrahim, Emad; Tripathy, Debu; Wilkinson, Mary; Hurvitz, Sara; Iannotti, Nicholas; Kellum, Andrew; Manalo, Yvonne; Wong, Serena; Hansen, Vincent; Alvarez, Ricardo; Chan, Arlene; Gore, Ira; Kendall, DiSean; Wade, James; Olek, Elizabeth; Hunt, Daniel; Fang, Pearl; Ebtahaj, Azita; Barcenas, Carlos H. Share Save
Incidence and severity of diarrhea with neratinib plus intensive loperamide prophylaxis in patients (pts) with HER2+early-stage breast cancer (EBC): Interim analysis from the multicenter, open-label, phase II control trial Barcenas, C.; Olek, E.; Hunt, D.; Tripathy, D.; Ibrahim, E.; Wilkinson, M.; Hurvitz, S.; Iannotti, N.; Kellum, A.; Manalo, Y.; Wong, S.; Hansen, V.; Alvarez, R.; Chan, A.; Gore, I.; Kendall, D.; Wade, J.; Ruiz, R.; Fang, P.; Bryce, R.; Moran, S. Share Save
PROSTATE SPECIFIC MEMBRANE ANTIGEN ANTIBODY DRUG CONJUGATE (PSMA ADC) IN PATIENTS (PTS) WITH PROGRESSIVE METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) FOLLOWING ABIRATERONE AND/OR ENZALUTAMIDE (ABI/ENZ): RESULTS FROM A PHASE 2 STUDY Petrylak, Daniel; Vogelzang, Nicholas; Chatta, Kamal; Fleming, Mark; Smith, David; Appleman, Leonard; Hussain, Arif; Modiano, Manuel; Singh, Parminder; Tagawa, Scott; Gore, Ira; McClay, Ed; Mega, Anthony; Sartor, Oliver; Somer, Brad; Wadlow, Raymond; Shore, Neal; Stambler, Nancy; DiPippo, Vincent; Israel, Robert Share Save
Effect of TOP2A and cMYC gene copy number on outcome in a Phase II trial of adjuvant TC (Docetaxel/Cyclophosphamide) plus trastuzumab (HER TC) in HER2-positive early stage breast cancer Jones, S.; Collea, R.; Paul, D.; Sedlacek, S.; Favret, A.; Gore, I.; Lindquist, D. L.; Holmes, F. A.; Allison, M. A. K.; Steinberg, M. S.; Stokoe, C.; Portillo, R. M.; Crockett, M.; Wang, Y.; Lina, A.; Robert, N. J.; O'Shaughnessy, J. Share Save
Share Save
Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR Bell, DW; Gore, I; Okimoto, RA; Godin-Heymann, N; Sordella, R; Mulloy, R; Sharma, SV; Brannigan, BW; Mohapatra, G; Settleman, J; Haber, DA Share Save
Share Save
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
Share.png){kind=icon}
Save
Not logged in.png){kind=icon}